[ad_1]
There is a potential hold back when looking for a corona vaccine. The pharmaceutical company AstraZeneca stops the last phase of testing because a test person is ill.
The pharmaceutical company AstraZeneca stopped the clinical study of its corona vaccine as a precautionary measure after one of the participants developed health problems. The British company announced that it was a routine measure for these cases. “Diseases occur randomly in a large series of experiments, but they have to be independently investigated to prove it thoroughly.”
AstraZeneca will expedite the investigation so that the vaccine approval process is delayed as little as possible, he said. The ultimate goal of the review is to determine if the health problems were caused by the vaccine. During the arrest, no more study participants should be vaccinated and people who have been vaccinated should continue to be observed.
Group assumes individual cases
AstraZeneca did not provide details of the side effects experienced by the subject, only of “a potentially unexplained illness.” The company is taking on an individual case. The vaccine is currently in the third and final phase of the study with several 10,000 participants.
The STAT news website first reported on the suspension of the study. A test person in the UK was ill, he said. An AstraZeneca spokesperson later confirmed a temporary test stop in the United States and other countries. In August, the pharmaceutical giant began recruiting 30,000 test subjects in the US for its largest study on the candidate vaccine.
The vaccine produced by the University of Oxford is also being tested in thousands of people in Britain, and there are smaller studies in Brazil and South Africa.
Final large-scale testing phases are also underway for two other candidate vaccines: one is manufactured by Moderna Inc., the other by Mainz-based biopharmaceutical company Biontech and its US partner Pfizer. These two vaccine hopefuls work differently than the AstraZeneca drug.
No compromises in the safety of Saxony
AstraZeneca and eight other pharmaceutical and biotech companies had only given guarantees Tuesday that they would not compromise safety by developing a corona vaccine.
This unusual move came in light of concerns that there could be political pressure, especially in the US, to urgently approve the first vaccines before the November 3 presidential election. The president of the United States, Donald Trump, promises almost daily that there will be a vaccine by the end of the year or possibly by the time of the elections.
